D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Masaru Matsuda, SVP, General Counsel and Corporate Secretary at Arcutis Biotherapeutics (NASDAQ:ARQT), a $1.8 billion market cap biopharmaceutical company with impressive gross profit margins of 88%, sold 6,330 shares of common stock on August 4, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $14.3266, for a total transaction value of $90,687.
The prices for the shares sold ranged from $13.965 to $14.675. The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units. The stock, which has delivered a remarkable 68.5% return over the past year, currently trades at $15.33 and appears slightly undervalued according to InvestingPro Fair Value estimates.
Following the transaction, Matsuda directly owns 197,364 shares of Arcutis Biotherapeutics, Inc., which includes 1,095 shares purchased under the Issuer’s Employee Stock Purchase Plan on May 31, 2025. Get deeper insights into ARQT’s valuation and 10+ additional exclusive InvestingPro Tips with a subscription.
In other recent news, Arcutis Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has approved its Zoryve topical foam 0.3% for treating plaque psoriasis on the scalp and body in individuals aged 12 and older. This marks the fifth approval for Zoryve in under three years, broadening treatment options for Americans with plaque psoriasis. The foam offers a steroid-free alternative, providing significant improvements in clinical trials, including rapid itch relief. In addition, H.C. Wainwright reiterated its Buy rating and $19 price target for Arcutis, following the FDA approval, highlighting the foam’s versatility for psoriasis treatment.
Morgan Stanley (NYSE:MS) has assumed coverage of Arcutis with an Overweight rating and a $20 price target, focusing on Zoryve’s commercial execution and market share gains. Guggenheim also maintained a Buy rating with a $29 price target, noting an increase in Zoryve prescriptions. Furthermore, H.C. Wainwright emphasized the strength of recent study data for Zoryve cream, underscoring its potential for long-term use in treating atopic dermatitis. The firm expressed confidence in the upcoming Prescription Drug User Fee Act (PDUFA) decision for Zoryve cream 0.05%, scheduled for October 13.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.